Company news

Aurinia Pharmaceuticals Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

September 19, 2022

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

September 18, 2022

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

August 3, 2022

Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review

July 25, 2022

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

July 24, 2022

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

July 21, 2022

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance

July 13, 2022

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

June 2, 2022

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

May 19, 2022

Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress

May 15, 2022

Aurinia Reports First Quarter 2022 Financial and Operational Results

May 9, 2022

Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022

May 5, 2022

Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022

May 1, 2022

Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis

April 18, 2022

Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings

April 3, 2022

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

March 2, 2022

Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates

February 27, 2022

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021

February 8, 2022

Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference

February 2, 2022

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

January 3, 2022

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)

December 8, 2021

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

November 9, 2021

Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates

November 2, 2021

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

October 31, 2021

Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021

October 26, 2021

Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021

October 25, 2021

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences

September 14, 2021

Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases

August 16, 2021

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference

August 8, 2021

Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights

August 4, 2021

Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021

July 25, 2021

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

July 15, 2021

Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs

June 29, 2021

Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)

June 24, 2021

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

June 13, 2021

Aurinia Announces Results of the 2021 Annual General Meeting

June 6, 2021

Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress

June 6, 2021

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

May 26, 2021

Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis

May 19, 2021

Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences

May 13, 2021

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

May 9, 2021

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet

May 9, 2021

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

May 5, 2021

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

April 27, 2021

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

April 14, 2021

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

April 7, 2021

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report

March 14, 2021

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

March 1, 2021

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

February 23, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.